B-Cell Non-Hodgkin's Lymphoma (NHL)
Oncology·MeSH: Lymphoma
Prevalence
30.0 / 100K
3 drugs in development·3 companies·1 clinical trial
Drug Pipeline by Phase
Phase 1(1)
| Drug | Company |
|---|---|
| prt2527 | Prelude Therapeutics Inc (PRLD) |
Phase 1/Phase 2(2)
Compare drugs
Frequently asked questions
How many drugs are in development for B-Cell Non-Hodgkin's Lymphoma (NHL)?
BioSniper tracks 3 drugs in development for B-Cell Non-Hodgkin's Lymphoma (NHL) across 3 companies.
How many clinical trials target B-Cell Non-Hodgkin's Lymphoma (NHL)?
There are 1 clinical trial targeting B-Cell Non-Hodgkin's Lymphoma (NHL) tracked by BioSniper.
What is the prevalence of B-Cell Non-Hodgkin's Lymphoma (NHL)?
The estimated prevalence of B-Cell Non-Hodgkin's Lymphoma (NHL) is approximately 30.0 per 100,000 population.
Deep-dive into B-Cell Non-Hodgkin's Lymphoma (NHL)
Full trial data, competitive analysis, and AI-powered pipeline tracking.
Start Free Analysis